Shinpoong Pharmaceutical Co Ltd Market Cap ($16.98 Million)
Market Cap & Net Worth: Shinpoong Pharmaceutical Co Ltd (019175)
Shinpoong Pharmaceutical Co Ltd market cap. Shinpoong Pharmaceutical Co Ltd (KO:019175) has a market capitalization of $16.98 Million (₩25.05 Billion) as of November 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #25468 globally and #1883 in its home market, demonstrating a -1.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shinpoong Pharmaceutical Co Ltd's stock price ₩12580.00 by its total outstanding shares 1991230 (1.99 Million). Also see cash efficiency ratio of Shinpoong Pharmaceutical Co Ltd for how efficiently the company converts equity into cash flow.
Shinpoong Pharmaceutical Co Ltd Market Cap History (2015–2026)
Shinpoong Pharmaceutical Co Ltd market cap history from 2015 to 2026. Data shows growth from $4.74 Million to $16.98 Million (11.77% CAGR). Check Shinpoong Pharmaceutical Co Ltd (019175) stock price for real-time trading data and today's change.
Shinpoong Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shinpoong Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Shinpoong Pharmaceutical Co Ltd growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Shinpoong Pharmaceutical Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
Shinpoong Pharmaceutical Co Ltd's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $5.44 Million | $194.15 Billion | -$18.59 Billion | 0.00x | N/A |
| 2017 | $6.31 Million | $185.00 Billion | $904.89 Million | 0.00x | 0.01x |
| 2018 | $7.93 Million | $187.39 Billion | $2.80 Billion | 0.00x | 0.00x |
| 2019 | $8.01 Million | $189.72 Billion | $5.32 Billion | 0.00x | 0.00x |
| 2020 | $164.82 Million | $197.75 Billion | $5.00 Billion | 0.00x | 0.03x |
| 2021 | $53.98 Million | $189.24 Billion | -$11.58 Billion | 0.00x | N/A |
| 2022 | $56.07 Million | $209.29 Billion | -$35.38 Billion | 0.00x | N/A |
| 2023 | $27.87 Million | $200.23 Billion | -$57.33 Billion | 0.00x | N/A |
| 2024 | $21.19 Million | $221.09 Billion | -$15.39 Billion | 0.00x | N/A |
| 2025 | $31.71 Million | $234.68 Billion | $8.83 Billion | 0.00x | 0.00x |
Competitor Companies of 019175 by Market Capitalization
Companies near Shinpoong Pharmaceutical Co Ltd in the global market cap rankings as of November 4, 2026. Also see 019175 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Shinpoong Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #509 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #534 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.90 |
| #580 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $46.03 Billion | CN¥49.31 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Shinpoong Pharmaceutical Co Ltd (2015–2026)
Market capitalization of Shinpoong Pharmaceutical Co Ltd from 2015 to today. Between 2015 and today, Shinpoong Pharmaceutical Co Ltd's market cap moved from $4.74 Million to $ 16.98 Million, with a yearly change of 11.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩16.98 Million | -46.47% |
| 2025 | ₩31.71 Million | +49.68% |
| 2024 | ₩21.19 Million | -23.97% |
| 2023 | ₩27.87 Million | -50.30% |
| 2022 | ₩56.07 Million | +3.88% |
| 2021 | ₩53.98 Million | -67.25% |
| 2020 | ₩164.82 Million | +1957.43% |
| 2019 | ₩8.01 Million | +1.02% |
| 2018 | ₩7.93 Million | +25.67% |
| 2017 | ₩6.31 Million | +16.07% |
| 2016 | ₩5.44 Million | +14.75% |
| 2015 | ₩4.74 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Shinpoong Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.98 Million USD |
| MoneyControl | $16.98 Million USD |
| MarketWatch | $16.98 Million USD |
| marketcap.company | $16.98 Million USD |
| Reuters | $16.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more